Firm
AJ Park’s owner, IPH, announced earlier this week that Steve Mitchell will take the reins of the New Zealand-based firm in January
Inès Garlantezec, who became principal of the firm’s Luxembourg office earlier this year, discusses what's been keeping her busy, including settling a long-running case
Rachel Cohen has reunited with her former colleagues to strengthen Weil’s IP litigation and strategy work
McKool Smith’s Jennifer Truelove explains how a joint effort between her firm and Irell & Manella secured a win for their client against Samsung
Sponsored
Sponsored
-
Sponsored by De Penning & De PenningAnand Barnabas and Anandan S of De Penning & De Penning explain how businesses with a strong technology and R&D focus can use freedom-to-operate searches to mitigate intellectual property infringement risks and target growth through innovation -
Sponsored by Bird & BirdMarijn van der Wal of Bird & Bird says a landmark Unified Patent Court case highlights the potential of expert witnesses to enhance patent litigation and shape procedural practices in Europe
-
Sponsored by Wanhuida Intellectual PropertyJicheng Yang and Jianhui Li of Wanhuida Intellectual Property draw on insights from CNIPA practice in discussing how different drafting approaches to crystal form patent claims impact protection scope and patent validity
-
Sponsored by RNA, Technology and IP AttorneysRanjan Narula, Swati Dalal, and Vanshika Oberoi of RNA, Technology and IP Attorneys explore the legal framework, challenges, and enforcement strategies for protecting well-known trademarks in India
-
Sponsored by Tilleke & GibbinsAdirek Siriwattasit of Tilleke & Gibbins says Thailand’s new fast-track patent programme for green technologies offers accelerated examinations at no extra cost to applicants, promotes sustainable innovation, and modernises the country’s intellectual property landscape
-
Sponsored by Hanol IP & LawMin Son of Hanol IP & Law says pharmaceutical R&D in South Korea should be enhanced on the introduction of a clearer legal framework that offers improved market protection for new and modified drugs
